文献速递毛发、甲与色素性疾病

0.2%噻唑基间苯二酚与4%氢醌治疗面部黄褐斑的随机对照试验

Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-06-07

该研究为评估者盲法随机对照试验,纳入50例面部黄褐斑女性,比较0.2% Thiamidol(每日两次)与4%氢醌(睡前)治疗90天的疗效与安全性。两组mMASI、MELASQoL及色差评分均显著改善,但组间无差异;Thiamidol组仅轻度不良反应,2例出现过敏性接触性皮炎。

要点

  • 0.2% Thiamidol与4%氢醌治疗面部黄褐斑疗效相当。
  • 两组mMASI、生活质量及色差改善均显著,组间无差异。
  • Thiamidol组不良反应轻微,但2例出现过敏性接触性皮炎。

核心结论

  • 0.2% Thiamidol治疗面部黄褐斑的改善程度与4%氢醌乳膏无差异。
  • Thiamidol可作为氢醌耐受性差或治疗失败黄褐斑患者的合适选择。

研究设计与样本

  • 纳入50例面部黄褐斑女性,随机分配至0.2% Thiamidol每日两次双层涂抹或4%氢醌乳膏睡前涂抹,疗程90天。
  • 两组均使用SPF60、PPD20的润色防晒霜。
  • 主要结局为基线黄褐斑面积严重指数(mMASI)评分变化;次要结局包括黄褐斑生活质量指数(MELASQoL)、色差计及全球美学改善量表(GAIS)评估。

主要发现

  • 氢醌组1例未完成研究(与不良反应无关)。
  • 参与者平均(SD)年龄43(6)岁,86%为III-IV型皮肤。
  • 两组mMASI、MELASQoL及色差评分均降低(P < 0.01)。
  • mMASI平均降低[95%置信区间(CI 95%)]:Thiamidol组43%(35-50%),氢醌组33%(23-42%)。
  • 两组在mMASI、MELASQoL、色差对比及GAIS评分降低方面无差异(P ≥ 0.09)。

关键数值与推荐

  • 主要结局mMASI降低:Thiamidol组43%(95%CI 35-50%),氢醌组33%(95%CI 23-42%)。
  • GAIS改善:Thiamidol组84%(95%CI 67-97%),氢醌组74%(95%CI 61-93%)。
  • 组间比较P ≥ 0.09。
  • Thiamidol组过敏性接触性皮炎发生率8%(2例)。

临床怎么用

  • 0.2% Thiamidol每日两次可作为面部黄褐斑的替代治疗选择。
  • 对于氢醌耐受性差或治疗失败的患者,可考虑使用Thiamidol。
  • 使用Thiamidol时需警惕过敏性接触性皮炎的可能。
  • 治疗期间应配合使用高防护防晒霜。

局限性

  • 样本量较小(50例)。
  • 研究周期较短(90天)。
  • 仅纳入女性,且86%为III-IV型皮肤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melasma can be refractory to treatment, and relapses are frequent. Thiamidol is a new potent tyrosinase inhibitor that has been found effective as a cosmeceutical for the depigmenting of melasma. OBJECTIVE: This study compared the efficacy and tolerability of topical 0.2% Thiamidol vs. 4% hydroquinone for facial melasma. METHODS: Fifty women with facial melasma participated in a randomized, evaluator-blinded, controlled study from September through November 2020. Patients were randomly assigned to apply a double layer of 0.2% Thiamidol twice a day or 4% hydroquinone cream at bedtime, for 90 days. Both groups received tinted sunscreen (sun protection factor 60, PPD 20). The primary outcome was the change from the baseline Modified Melasma Area Seve:rity Index (mMASI) score. Secondary outcomes were improvements in the patients' quality of life [Melasma Quality of Life Index (MELASQoL)], colourimetry, and Global Aesthetic Improvement Scale (GAIS) evaluation. RESULTS: One participant, from the hydroquinone group, did not complete the study (unrelated to adverse effects). The mean (SD) age of the participants was 43 (6) years, and 86% were phototypes III-IV. Both groups exhibited a reduction in mMASI, MELASQoL, and colour contrast scores (P < 0.01). The mean [95% confidence interval (CI 95%)] reductions of the mMASI scores were 43% (35-50%) for Thiamidol and 33% (23-42%) for hydroquinone. There was no difference between the groups in the reductions in mMASI, MELASQoL, colourimetric contrast and GAIS scores (P ≥ 0.09). The GAIS analysis resulted in an improvement of 84% (CI: 95% 67-97%) for participants in the Thiamidol group and 74% (CI: 95% 61-93%) for those in the hydroquinone group. There were only mild adverse effects in the Thiamidol group, but allergic contact dermatitis was evidenced in two (8%) participants. CONCLUSION: The melasma improvement achieved using 0.2% Thiamidol did not differ from that of 4% hydroquinone cream. Thiamidol can be considered a suitable option for melasma patients with poor tolerability or treatment failure with hydroquinone.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lima PB, Dias JAF, Cassiano DP, et al. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol. 2021. PMID: 33988887. doi:10.1111/jdv.17344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。